Niemann-Pick Type C Before Age 6, What Adrabetadex Could Change on November 17th and Who Today's Medicines Leave Out

By November 17th, the FDA is due to decide whether adrabetadex becomes the first medicine approved for infantile-onset Niemann-Pick disease type C. That name covers children whose nerve and brain symptoms began before age 6, according to the drug's maker, Beren Therapeutics. For parents, guardians and caregivers of a baby or toddler with NPC, the decision matters for a plain reason. The 2 medicines approved today have labels that start at age 2 or at 15kg, about 33 pounds, and the drug studies now enrolling start at age 4.

Adrabetadex also carries an unusual past, which began with a request filed for twin girls on December 1, 2008. Four companies have held the drug since then. One of those companies ended the program in 2021 and recommended that children stop treatment.

Which Niemann-Pick Type C Medicines Can a Child Under 2 Get Today?

No medicine approved in the US for Niemann-Pick disease type C is labeled for a child under 2 who weighs less than 15kg. Miplyffa (arimoclomol) is labeled from age 2 and must be taken with miglustat. Aqneursa (levacetylleucine) is labeled by weight, starting at 15kg.

That gap shows up when 3 records are read side by side, as Trial Friend did on November 11, 2026. The Miplyffa label says 2 years of age and older, and its smallest dose band runs from 8kg to 15kg. The Aqneursa label covers adults and children weighing 15kg or more, with no age stated. ClinicalTrials.gov lists 4 NPC drug studies that are recruiting or about to recruit, and each sets a minimum age of 4.

A 2-year-old who weighs 10kg sits inside the Miplyffa label and outside the Aqneursa label. Doctors sometimes prescribe approved medicines outside their labels, which is a decision for the specialist and the family.

Adrabetadex is absent from that grid because it has no label yet. Beren asked for a group defined by when symptoms began, before age 6, so its age and weight rules will be known only if the FDA approves it.

Infantile-onset Niemann-Pick type C means the first nerve or brain symptoms appeared before age 6, in the definition Beren uses in its FDA application. Doctors split that span in 2, and GeneReviews, the genetics reference hosted by the National Institutes of Health, names each half. Onset before age 2 is called early infantile, and onset from 2 to under 6 is called late infantile.

NPC is inherited when a child receives a changed copy of the NPC1 or NPC2 gene from each parent. The NPC1 gene accounts for about 95% of cases (GeneReviews, updated November 2025). Cholesterol and other fats then build up inside cells, which harms the liver, spleen and brain. The first signs in a baby are often jaundice that lingers, a large liver or spleen, low muscle tone and late milestones.

Age at first symptom matters because it tracks with how fast the disease moves. In an international registry of 145 patients, 11% had early infantile onset and 31% had late infantile onset (Patterson et al., 2013). A 2010 review in the Orphanet Journal of Rare Diseases described a severe early infantile form in which survival rarely passed 5 years (Vanier, 2010). Both papers predate the 2 medicines approved in 2024.

How a 2008 Request for Twin Girls Became Adrabetadex

On December 1, 2008, Dr. Caroline Hastings of Oakland, California, sent the FDA 2 requests to treat identical twins with a sugar molecule called cyclodextrin (Hastings et al., 2019). The twins belonged to the Hempel family of Reno, Nevada, and had been diagnosed the year before, PBS NOVA Next reported in 2016. Their parents had pressed drug companies, the FDA and doctors to allow the treatment, according to that report.

The girls first received cyclodextrin through a vein in 2009. Their doctors began placing it directly into the spinal fluid in 2010, about 18 months later (Hastings et al., 2019). Adrabetadex is given by that same route today.

The National Institutes of Health then ran the first formal study, starting in 2013. Its results, published in The Lancet in 2017, covered 14 participants aged 4 to 23. Their disease scores worsened by 1.22 points a year, against 2.92 points in 21 untreated patients followed earlier (Ory et al., 2017).

Companies followed the science, starting with Vtesse, which launched in January 2015 to develop the drug as VTS-270. Sucampo bought Vtesse in April 2017, BioSpace reported. Mallinckrodt then bought Sucampo and has said it took over the compound in February 2018.

A larger randomized trial then did not show a difference. On November 6, 2018, Mallinckrodt told families that the drug had not separated from the sham procedure in a statistically significant way. Neither group had worsened over the year, the company wrote.

Mallinckrodt wrote to families again on January 20, 2021. Its letter said there was "no clear evidence of potential benefit," called the balance of benefit and risk negative, and recommended ending treatment. Supply for children already on the drug would last until October 20, 2021, and no new patients could start.

Beren Therapeutics stepped in before that deadline through its subsidiary, Mandos. Mandos completed the purchase of adrabetadex on July 1, 2021, after a bankruptcy court approved the sale. It also pledged to keep the North American access program running (Business Wire, 2021). Beren says the program's lead doctor, Elizabeth Berry-Kravis of Rush University, then proposed checking whether treated children were living longer.

What Evidence Is the FDA Weighing for Adrabetadex?

The adrabetadex application rests mainly on a survival comparison, according to Beren. It matched 72 treated children with infantile-onset NPC to 119 untreated children from earlier records. Beren reported that treated children had a 71% lower risk of death, and that 84% were alive at 5 years against 42% of the comparison group.

Those numbers come from company releases and a meeting poster, and Trial Friend found no journal publication of them as of November 11, 2026. The comparison was not randomized, and the 2 groups differed in where they lived. Beren's poster shows that 85% of treated children lived in North America, while 76% of the comparison children were European. The poster's data stop at January 10, 2025, so later outcomes are not included.

The one randomized trial did not show a benefit, and it included no infants. It enrolled 56 people aged 4 to 21 and excluded anyone under 15kg (ClinicalTrials.gov, NCT02534844). After 52 weeks, the main score had changed by 0.0 points on adrabetadex and by minus 0.1 on the sham procedure.

The drug's standing with the FDA has changed more than once. Beren says the agency withdrew an earlier Breakthrough Therapy designation after that trial and granted a new one on December 9, 2025. The agency accepted the application in February 2026 and later moved its goal date from August 17th to November 17th. Beren's explanation was that the FDA treated its March 18th reply to a data question as a major amendment.

Hearing Loss and Spinal Injections, the Known Burdens of Adrabetadex

Hearing loss is the best-documented side effect of adrabetadex. In the NIH study, all 14 participants lost some mid-range to high-range hearing (Ory et al., 2017). All 14 became candidates for hearing aids, although 7 of them already were at the start. In the randomized trial, the hearing score worsened by 1.14 points on the drug and improved by 0.22 on the sham procedure. Beren describes hearing impairment as manageable with hearing aids when needed.

The route is the other burden, because adrabetadex was given by lumbar puncture every 2 weeks in the studies, with or without general anesthesia. Rush University doctors counted 2,935 infusions in 59 patients over 9 years and recorded side effects after 3.3% of them, mostly headache, vomiting and back pain (Albert et al., 2023). A separate report found a major anesthesia event, such as a drop in oxygen, in 5 of 394 sessions (Ulloa et al., 2020).

Beren has not published the dose or schedule it asked the FDA to approve. Its October 2026 poster says children in the access program started at 200mg or 400mg, depending on age, every 2 weeks.

What an Approval or a Rejection on November 17th Would Mean for Families

A second cyclodextrin medicine now sits behind adrabetadex in the FDA's queue. Rafael Holdings asked the FDA on October 29, 2026 to approve Trappsol Cyclo, given into a vein and now named remibetadex, for NPC from birth. The company had reported on September 30th that its main trial missed its primary goal. It is a different product from adrabetadex, although the 2 share a history, because the twins' first infusions in 2009 used Trappsol Cyclo (Hastings et al., 2019).

Steps a Family Can Line Up Around the Adrabetadex Decision

• Ask the clinic how the first nerve or brain symptom is dated in the medical record, because the application defines its group by symptoms that began before age 6.
• Find out whether a recent hearing test is on file, since hearing changes were common in the adrabetadex studies.
• The access program takes requests from a child's own doctor and judges each one case by case, and Beren says more than 60 patients are enrolled.
• The National Niemann-Pick Disease Foundation offers eligible member families up to $1,000 every 12 months toward costs such as medical equipment and utility bills. According to the foundation, its 6-month membership rule does not apply to newly diagnosed families, and its family services line is 877-287-3672.
• Families still waiting on a genetic answer can look at Test for NPC, a program in which Beren pays for genome sequencing through the laboratory GeneDx.

Trial Friend lists the NPC studies that are open, with ages and locations, on the Niemann-Pick type C page. The FDA calendar entry for adrabetadex carries the live status, and the signup on this page sends one email when the FDA decides.

December 1, 2008 to November 17, 2026 is 6,560 days. More than 60 patients are receiving adrabetadex through the access program while the FDA finishes its review, Beren says, and this page will carry the outcome.

Adrabetadex and Niemann-Pick Type C Questions Parents Search